We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

86 hedge funds and large institutions have $26.8M invested in Tetraphase Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 32 increasing their positions, 22 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 22

7% less funds holding

Funds holding: 9286 (-6)

30% less call options, than puts

Call options by funds: $26K | Put options by funds: $37K

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

58% less capital invested

Capital invested by funds: $63.4M → $26.8M (-$36.6M)

Holders
86
Holders Change
-6
Holders Change %
-6.52%
% of All Funds
1.92%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
32
Reduced
22
Closed
14
Calls
$26K
Puts
$37K
Net Calls
-$11K
Net Calls Change
-$253K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$4.33M -$950K -24,294 -11%
Dimensional Fund Advisors
2
Dimensional Fund Advisors
Texas
$2.84M -$2.62K -67 -0.1%
Renaissance Technologies
3
Renaissance Technologies
New York
$2.75M +$3.04M +77,813 +178%
State Street
4
State Street
Massachusetts
$1.42M +$99.1K +2,535 +4%
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.24M -$2.24M -57,403 -51%
Deutsche Bank
6
Deutsche Bank
Germany
$1.17M +$1.79M +45,686 +721%
TCM
7
Tekla Capital Management
Massachusetts
$971K
6CM
8
683 Capital Management
New York
$893K +$148K +3,774 +11%
Two Sigma Investments
9
Two Sigma Investments
New York
$888K +$540K +13,798 +54%
Northern Trust
10
Northern Trust
Illinois
$809K -$607K -15,527 -30%
Man Group
11
Man Group
United Kingdom
$742K -$446K -11,402 -26%
JP Morgan Chase
12
JP Morgan Chase
New York
$709K +$45.4K +1,160 +4%
OAM
13
Oxford Asset Management
United Kingdom
$661K +$840K +21,474 +277%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$623K +$42.7K +1,093 +4%
RA
15
Royce & Associates
New York
$539K
UBS Group
16
UBS Group
Switzerland
$445K +$215K +5,489 +39%
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$436K -$94.2K -2,410 -11%
AFM
18
Anson Funds Management
Texas
$380K +$657K +16,797 New
Jacobs Levy Equity Management
19
Jacobs Levy Equity Management
New Jersey
$299K +$201K +5,148 +64%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$250K +$144K +3,695 +50%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$237K -$1.25K -32 -0.3%
Goldman Sachs
22
Goldman Sachs
New York
$233K +$5.04K +129 +1%
Morgan Stanley
23
Morgan Stanley
New York
$209K -$172K -4,403 -32%
AQR Capital Management
24
AQR Capital Management
Connecticut
$207K +$358K +9,167 New
PPA
25
Parametric Portfolio Associates
Washington
$187K +$68.2K +1,744 +27%

TTPH Hedge Fund Activity: Q4 2018 in Review

86 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q4 2018, worth a combined $26.8M — down 58% from $63.4M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of TTPH and 8 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 32 added.

The largest buyer was Renaissance Technologies, adding an estimated $3.04M. The largest seller was Vanguard Group, cutting an estimated $2.24M.

  • 86 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q4 2018, down from 92 in Q3 2018.
  • Funds reported $26.8M of Tetraphase Pharmaceuticals, Inc. stock for Q4 2018, down 58% quarter-over-quarter.
  • 8 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q4 2018 and 14 closed out, a net change of -6 holders.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q4 2018 was Renaissance Technologies, an estimated $3.04M added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q4 2018 was Vanguard Group, an estimated $2.24M sold.

Based on aggregated 13F filings for Q4 2018.